Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 6/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.53 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.53 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.53 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.41 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10553508 | 0.91 | ALDH1A1 (0.53) | LMNAEGLN1ALKBH5SUCNR1ABCC4 | |
| Hydrogen Peroxide SCHEMBL27498555 | 0.91 | — | — | |
| SCHEMBL23108 | 0.91 | — | — | |
| SCHEMBL10554896 | 0.91 | ALDH1A1 (0.53) | LMNAEGLN1ALKBH5SUCNR1ABCC4 | |
| SCHEMBL9335555 | 0.91 | ALDH1A1 (0.53) | LMNAEGLN1ALKBH5SUCNR1ABCC4 | |
| Adipic Acid SCHEMBL9301250 | 0.89 | ABCC4 (0.62) | LMNAABCC4MAPTCYP2D6ALDH1A1 | |
| SCHEMBL9860296 | 0.88 | — | — | |
| Bromide SCHEMBL11761228 | 0.88 | — | — | |
| Ammonia Solution, Strong SCHEMBL462357 | 0.88 | — | — | |
| Methane SCHEMBL20636856 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3137060-B2 | EXTENDED RELEASE SUSPENSION COMPOSITIONS | SUN PHARMACEUTICAL IND LTD (IN) | 2023-12-20 | — | — | EP | claimed |
| EP-3137060-B1 | EXTENDED RELEASE SUSPENSION COMPOSITIONS | SUN PHARMACEUTICAL IND LTD (IN) | 2020-11-11 | — | — | EP | claimed |
| EP-3137057-B1 | EXTENDED RELEASE LIQUID COMPOSITIONS OF METFORMIN | SUN PHARMACEUTICAL IND LTD (IN) | 2020-09-09 | — | — | EP | claimed |
| EP-1749519-A1 | Dosage form with pH-independent sustained release for active substances with pH-dependent solubility | Schering Aktiengesellschaft (DE) | 2007-02-07 | — | — | EP | claimed |
| EP-4384148-A1 | ENTERIC-COATED PARTICLES CONTAINING LACTOFERRIN | Univerza V Ljubljani (SI) | 2024-06-19 | — | — | EP | disclosed |
| EP-3630074-B1 | MULTIPARTICULATE ORAL DOSAGE FORM PROVIDING PROLONGED RELEASE OF TAPENTADOL | GRUENENTHAL GMBH (DE) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023036981-A1 | ENTERIC-COATED PARTICLES CONTAINING LACTOFERRIN | UNIVERZA V LJUBLJANI (SI) | 2023-03-16 | — | — | WO | disclosed |
| US-10842752-B2 | Pharmaceutical or nutraceutical composition with sustained release characteristic and with resistance against the influence of ethanol | EVONIK OPERATIONS GMBH (DE) | 2020-11-24 | — | — | US | disclosed |
| US-10639283-B2 | Gastric resistant pharmaceutical or nutraceutical composition with resistance against the influence of ethanol | EVONIK OPERATIONS GMBH (DE) | 2020-05-05 | — | — | US | disclosed |
| EP-3630074-A1 | MULTIPARTICULATE ORAL DOSAGE FORM PROVIDING PROLONGED RELEASE OF TAPENTADOL | Grünenthal GmbH (DE) | 2020-04-08 | — | — | EP | disclosed |
| US-20180369151-A1 | MULTIPARTICULATE ORAL DOSAGE FORM PROVIDING PROLONGED RELEASE OF TAPENTADOL | Grünenthal GmbH (DE) | 2018-12-27 | — | — | US | disclosed |
| WO-2018219897-A1 | MULTIPARTICULATE ORAL DOSAGE FORM PROVIDING PROLONGED RELEASE OF TAPENTADOL | Grünenthal GmbH (DE) | 2018-12-06 | — | — | WO | disclosed |
| WO-2015121189-A1 | PHARMACEUTICAL OR NUTRACEUTICAL COMPOSITION WITH SUSTAINED RELEASE CHARACTERISTIC AND WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL | EVONIK INDUSTRIES AG (DE) | 2015-08-20 | — | — | WO | disclosed |
| US-20150209298-A1 | GASTRIC RESISTANT PHARMACEUTICAL OR NUTRACEUTICAL COMPOSITION WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL | EVONIK INDUSTRIES AG (DE) | 2015-07-30 | — | — | US | disclosed |
| US-20150190348-A1 | PHARMACEUTICAL OR NUTRACEUTICAL COMPOSITION WITH SUSTAINED RELEASE CHARACTERISTIC AND WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL | EVONIK INDUSTRIES AG (DE) | 2015-07-09 | — | — | US | disclosed |
| EP-2887925-A1 | GASTRIC RESISTANT PHARMACEUTICAL OR NUTRACEUTICAL COMPOSITION WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL | Evonik Industries AG (DE) | 2015-07-01 | — | — | EP | disclosed |
| EP-2887926-A1 | PHARMACEUTICAL OR NUTRACEUTICAL COMPOSITION WITH SUSTAINED RELEASE CHARACTERISTIC AND WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL | Evonik Industries AG (DE) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014032742-A1 | PHARMACEUTICAL OR NUTRACEUTICAL COMPOSITION WITH SUSTAINED RELEASE CHARACTERISTIC AND WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL | EVONIK INDUSTRIES AG (DE) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014032741-A1 | GASTRIC RESISTANT PHARMACEUTICAL OR NUTRACEUTICAL COMPOSITION WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL | EVONIK INDUSTRIES AG (DE) | 2014-03-06 | — | — | WO | disclosed |
| EP-1749519-A1 | Dosage form with pH-independent sustained release for active substances with pH-dependent solubility | Schering Aktiengesellschaft (DE) | 2007-02-07 | — | — | EP | disclosed |